Liver X receptors studied as a new class of cancer meds

Two researchers at the University of Houston say that recent work highlights the promise of liver X receptors, or LXRs, as a target for hard-to-treat cases of pancreatic cancer.

New method uses coated gold nanorods to treat pain

Tiny gold nanorods have been the subject of a number of preclinical studies. Now a team at the University of Kyoto in Japan says they coated the ultrathin rods with a fat-transporting protein and found that it could be a very effective treatment for pain.

UCSF cardiology chief builds a case for two new targets for heart drugs

Following up on some promising rodent studies, a team of investigators at UC San Francisco has helped substantiate that elevated levels of two proteins are linked with healthier hearts--an insight that will likely inspire more work into new cardiology therapies.

TSRI researchers spotlight a hidden cause of antibiotics resistance

A team at The Scripps Research Institute (TSRI) have characterized a novel set of genes that are "switched on" during drug resistance of the important human pathogen—Staphylococcus aureus.

UC Berkeley team says brown fat implants may effectively tackle obesity

A team of scientists at UC Berkeley have developed a technique that utilizes the protective effects of brown fat--which may potentially lead to a new approach to manage obesity, diabetes and other metabolic disorders.

MSK: 'This is what the future of precision medicine looks like'

Investigators at Memorial Sloan Kettering Cancer Center have changed the rules of the clinical trial game in the first of what they say will be a new wave of studies that examine a drug's potential based on a broad patient population who share the same genetic mutation rather than cancer type.

MD Anderson spotlights role of cytokine in tumor progression

There's a well-known link between the activation of epidermal growth factor receptors (EGFR) and tumor progression. Now scientists at MD Anderson in Texas can be shut down with the help of a cytokine called macrophage migration inhibitory factor, or MIF.

Study: Eyes may signal brain pathology in schizophrenia

For years researchers have worked with assumptions that abnormalities in the way the brain processes vision contributed to severe problems with the way schizophrenics handled social interactions or distinguished between what's real or not real. But investigators from Mt. Sinai and Rutgers say that a review of the literature revealed structural changes in the eyes of schizophrenics are also linked to the disease, an insight that could eventually change the way the disease is diagnosed and treated.

Is the biomedical research system broken? Johns Hopkins says yes

Researchers at the Johns Hopkins Bloomberg School of Public Health took a close look at the state of affairs in the drug research business over the past 50 years, and found plenty of reasons for despair.

Harvard/MIT group sees promise of a targeted IBD drug delivery tech

A group of specialists drawn from Brigham and Women's Hospital, Mass General and MIT have come up with a new delivery technology that they believe could make a radical difference for patients suffering from inflammatory bowel disease.

Johns Hopkins team uses zebrafish to develop a new drug screening tech

High throughput screening was once viewed as the very salvation of the drug development world. The automated system developed in the '80s could test hundreds of potential drugs in robotic fashion, looking for the telltale "hits" that could flag a possible new therapy. The problem, though, was that the effects they were seeing with HTS screening rarely translated in more complex animal models--or stood a chance in humans.

New insights into T cells could help immuno-oncology, autoimmune R&D

Orchestrating an immune response, either by turning the immune system on or switching it off, is one of the biggest, hottest fields in drug R&D. And now a team of investigators at UC Davis say that they discovered a mechanism that may help research into immuno-oncology as well as autoimmune conditions like multiple sclerosis.

Vitamin B3 pathway may lead to new obesity drugs

Researchers at Beth Israel Deaconess Medical Center say that a newly discovered vitamin B3 pathway could prove fruitful in pursuing new drugs for obesity, diabetes and other metabolic conditions.

MGH study pinpoints a genetic trigger for heart valve disorder

Mutations in a gene called DCHS1 are believed to be at the root of a heart valve disorder called mitral valve prolapse, according to investigators at Massachusetts General Hospital. And understanding the way these mutations play out should help drug developers come up with new therapies to correct the condition.

UBC team stakes a claim on a newly discovered 'obesity gene'

By silencing a gene which encodes the protein 14-3-3zeta, scientists at the University of British Columbia say they were able to halve the amount of white fat in mice, possibly opening the door to a new approach to fighting obesity.

Salk team spotlights a new mGluR5 target for schizophrenia, autism

Investigators at the Salk Institute have blazed a new trail branching out from the closely studied mGluR5 pathway in the brain, and they say it could ultimately lead to new therapies to treat neurodevelopmental disorders like autism and schizophrenia.

Overstimulating oncogene family SRC shows promise against cancer

Researchers at Baylor College of Medicine have overstimulated cancer cells with a new drug candidate called MCB-613, showing promise in preventing tumor growth.

TSRI researchers say enzyme may work as an antismoking treatment

Recent work by scientists at The Scripps Research Institute (TSRI) has spotlighted a bacterial enzyme and its potential as a drug candidate to alleviate an addiction to tobacco.

Virus-like nanoparticle vaccine used to guard against RSV

Researchers at Georgia State University say they created a new RSV vaccine from virus-like nanoparticles. The respiratory virus infects the lungs and breathing passageways.

BU researchers identify a new, more precise target for breast cancer

A new biomarker for lethal cases of basal-like breast cancer (BLBC) could provide a new and more precise target for cancer drug developers. Researchers at Boston University say they found that a molecule named IL13RA2 (IL13R alpha2) is found clustered on the surface of BLBC cells among late-stage and metastatic cases, when the disease is almost impossible to slow down.